Chris O'Reilly
Head of Investor Relations
Replay available
Takeda Pharmaceutical Company Limited (TAK) Q3 2024 Earnings Call
Takeda Pharmaceutical Company Limited (NYSE: TAK) Q3 2024 earnings conference call, held 2025-01-30. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Christopher Weber
President and CEO
Milano Furuta
Chief Financial Officer
Andy Pram
President, Research & Development
Steve Barker
Analyst, Jefferies
Siti Yamaguchi
Analyst
Mike Nedeljkovic
Analyst, TD Cowen
Tony Ren
Analyst, Macquarie
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Takeda Pharmaceutical Co. Ltd..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.225 Thank you for joining us today, despite a very busy schedule, for FY24 Q3 earnings 00:00:05.225 -- 00:00:07.990 call by Takeda. 00:00:08.165 -- 00:00:10.949 I'm the master of the ceremony today, head of IR. 00:00:10.949 -- 00:00:14.033 My name is O'Reilly. Thank you for this opportunity. 00:00:14.033 -- 00:00:17.317 I would like to explain about the language setting first. 00:00:17.317 -- 00:00:21.663 Please find the button for the language selection at the bottom of the Zoom window. 00:00:21.663 -- 00:00:25.127 If you wish to listen in Japanese, please select Japanese. 00:00:25.127 -- 00:00:28.772 If you wish to listen to English, please select English. 00:00:28.772 -- 00:00:33.679 Or if you want to listen to the original language, please keep it off. 00:00:33.679 -- 00:00:38.022 Please select English in the Zoom language select button. 00:00:38.624 -- 00:00:40.587 Before 00:00:40.587 -- 00:00:42.587 starting, 00:00:44.653 -- 00:00:48.018 I'd like to remind everyone that we'll be discussing forward-looking statements within 00:00:48.018 -- 00:00:53.025 the meaning of the Private Securities Litigation Reform Act of 1995. 00:00:53.025 -- 00:00:57.729 Actual results may differ materially from those discussed today. 00:00:57.752 -- 00:01:02.018 The factors that could cause actual results to differ materially are discussed in our 00:01:02.018 -- 00:01:07.514 most recent Form 20F and our other SEC filings. 00:01:07.514 -- 00:01:09.514 Please 00:01:11.058 -- 00:01:15.702 also refer to the important notice on page 2 of the presentation regarding forward-looking 00:01:15.702 -- 00:01:20.187 statements and our non-IFRS financial measures, which we will also be discussing during 00:01:20.187 -- 00:01:25.450 this call. Definitions of our non-...